Science Explorer Back to mapMap
Discussion

NovaDigm Therapeutics (United States)

Research works
4
▼ 100% vs 2018-21
Citations
150
33.3 per fractional work
Top-10% rate
18.4%
all institutions 10.0%
Open access
54%
world 40%

Not ranked overall: NovaDigm Therapeutics (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does NovaDigm Therapeutics (United States) work in?

In all years, 61% of research at NovaDigm Therapeutics (United States) is in Health Sciences, 28% in Life Sciences. Its largest fields are Medicine (59%), Immunology and Microbiology (24%), Engineering (7%). It does 1.4× the world's share of Health Sciences.

Life Sciences28%Physical Sciences11%Health Sciences61%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 6 fields, with their numbers
    1. Medicine358.7%
    2. Health Professions02.2%
    1. Immunology and Microbiology123.9%
    2. Biochemistry, Genetics and Molecular Biology04.3%
    1. Engineering06.5%
    2. Environmental Science04.3%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

    Who are the top researchers at NovaDigm Therapeutics (United States)?

    Ranked on the quality score, Clint S. Schmidt and John P. Hennessey lead among researchers whose main affiliation is NovaDigm Therapeutics (United States).

    1. 1 Clint S. Schmidt United States · #792,938 worldwide 2.3k citations · 27 works
    2. 2 John P. Hennessey United States · #1,311,114 worldwide 2.5k citations · 53 works
    All ranked researchers at NovaDigm Therapeutics (United States)

    What are the most cited papers from NovaDigm Therapeutics (United States)?

    The most cited paper from NovaDigm Therapeutics (United States) is "NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults" (Clint S. Schmidt, C. J. White, Ashraf S. Ibrahim et al., 2012), with 233 citations. Next come "A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis—A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial" (215) and "NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response" (102).

    Most cited papers
    #PaperReleasedCitations
    1 NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults Clint S. Schmidt, C. J. White, Ashraf S. Ibrahim et al. · Vaccine Open access 22 Oct 2012 233
    2 A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis—A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial John Ernest Edwards et al. · Clinical Infectious Diseases Open access Mar 2018 215
    3 NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response Ashraf S. Ibrahim, Guanpingsheng Luo, Teclegiorgis Gebremariam et al. · Vaccine Open access 21 Sep 2013 102
    4 Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection Michael R. Yeaman, Scott G. Filler, Siyang Chaili et al. · Proceedings of the National Academy of Sciences Open access 8 Dec 2014 77
    5 Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis Priya Uppuluri, Shakti Singh, Abdullah Alqarihi et al. · Frontiers in Immunology Open access 15 Jun 2018 59
    All 14 most cited papers, with filters and sorting

    Which research topics does NovaDigm Therapeutics (United States) publish most on?

    By volume: Antifungal resistance and susceptibility, Reproductive tract infections research, Immunodeficiency and Autoimmune Disorders and Monoclonal and Polyclonal Antibodies Research.

    1. 1 Antifungal resistance and susceptibility Infectious Diseases 1 works
    2. 2 Reproductive tract infections research Microbiology 0 works
    3. 3 Immunodeficiency and Autoimmune Disorders Immunology 0 works
    4. 4 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 0 works
    5. 5 Antimicrobial Resistance in Staphylococcus Infectious Diseases 0 works
    6. 6 Biomedical and Engineering Education Biomedical Engineering 0 works
    7. 7 Biotechnology and Related Fields Public Health, Environmental and Occupational Health 0 works
    8. 8 Immunotherapy and Immune Responses Immunology 0 works
    9. 9 vaccines and immunoinformatics approaches Molecular Biology 0 works
    10. 10 Fungal Infections and Studies Epidemiology 0 works

    How open and international is its research?

    Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

    openly available53.7%not open46.3%

    World: 40% of research is openly available.

    How has NovaDigm Therapeutics (United States)'s research output changed?

    Output in 2022-2025 was 100% lower than in 2018-2021.

    20152020
    grewheldshrank

    The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

    Other research institutions in Grand Forks

    All research institutions in Grand Forks

    Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

    Discussion

    Ask a question or share a note about NovaDigm Therapeutics (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.